Sdz 215-811
| Code | Size | Price |
|---|
| TAR-T34592-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Sdz 215-811 is a potential radiopharmaceutical used in somatostatin receptor-positive tumors imaging.
CAS:
142694-57-3
Formula:
C63H85N13O20S2
Molecular Weight:
1408.56
Purity:
0.98
SMILES:
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(=O)N1)C(O)=O
References
Hardiansyah D, Begum NJ, Kletting P, Mottaghy FM, Glatting G. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy. Cancer Biother Radiopharm. 2016 Aug;31(6):217-24. doi: 10.1089/cbr.2016.2012. Epub 2016 Jul 12. PubMed PMID: 27403777.
Bruns C, Stolz B, Albert R, Marbach P, Pless J. OctreoScan 111 for imaging of a somatostatin receptor-positive islet cell tumor in rat. Horm Metab Res Suppl. 1993;27:5-11. PubMed PMID: 8392488.
Harrison CE, Barron BJ. MIBG superscan of metastatic paraganglioma occurring with neurofibromatosis type 1. Clin Nucl Med. 2013 Jun;38(6):459-62. doi: 10.1097/RLU.0b013e3182816777. PubMed PMID: 23455526.
Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, et al. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991;49(22):1583-91. PubMed PMID: 1658515.